Epitomee Medical Ltd · TASE:EPIT
Epitomee Medical — Investor Presentation (September 2026)
35 slides from Epitomee Medical's investor presentation, September 2026
Slide 1: Business Focus & Growth Strategy: US Weight Management Market
Business Focus & Growth Strategy US Weight Management Market Investor Presentation September 2026 1
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) is for informational purposes only and does not constitute or form any part of any offer or solicitation to buy or subscribe for securities of Epitomee Medical Ltd. (the “Company”) and should not be regarded as a recommendation or an opinion on such
Slide 3: Management Team
Management Team Shimon Eckhouse, PhD Dolev Rafaeli, PhD Co-founder and Chairman Chief Executive Officer Founder of Syneron NASDAQ: ELOS & Lumenis CEO Radiancy Inc; NASDAQ: LMNS, Sofwave Medical TLV: SOFW and others CEO PhotoMedex Inc (NASDAQ: PHMD); CEO and Vice Chair Strata Skin Sciences (NASDAQ: S
Slide 4: Epitomee's Strategic Focus Areas: Current Market and Pipeline
Epitomee’s Strategic Focus Areas: Current Market and Pipeline Current Pipeline Weight Management Biologics Drug Market 2: market1: size and trends size and trends ~$180B ~$0.5T ~$400B+ by 2035 ~$1T+ by 2035 1. Based on Towards Health Care market report 2026- 2. Based on Precedence Research 2026 – ht
Slide 5: GLP-1 Market Size Outlook
GLP-1 Market Size Outlook Global GLP-1 market $180 • This growth is driven by $160 $157B rising obesity rates and $140 advancements in weight $120 management products. $Billion $100 $80 $62B $60 $40 $20 $- 2025 2035 ResearchAndMarkets.com, Jan 2026 Note: Market size estimates vary significantly dep
Slide 6: The GLP-1 success created the weight maintenance gap
The GLP-1 success created the “weight maintenance” gap; the Epitomee® capsule is closing it 65% of GLP-1 users stop using the medication. 2/3 experience rapid 65% weight regain after Discontinue stopping within the initial 12 50% experience side months effects, short- & long-term Post GLP-1 users re
Slide 7: US Market: Over 170M US patients are eligible for Epitomee
US Market :Over 170M US patients are eligible for Epitomee® Million patients, current state 22M Epitomee® Entry Market SOM: patients aligned with Epitomee® Epitomee® value proposition (seeking up to 10% weight Entry Market loss, maintenance or intolerant to GLP-1) SOM 70M Patients with mild/no comor
Slide 8: The Epitomee Capsule
The Epitomee® Capsule © eet epitemee
Slide 9: How the Epitomee Capsule Works
How the Epitomee® Capsule Works 9
Slide 10: Epitomee: An Alternative for a Wider Audience BMI 25 to 40
Epitomee : An Alternative for a Wider Audience ® Patients seeking a long-term, side-effect-free alternative post GLP-1 therapy Epitomee® capsule offers a weight-management solution. Indicated for adults: BMI 25 to 40 Including those who are ineligible for GLP-1 Target Patient Segments: • Post GLP-1
Slide 11: Epitomee Capsule
Epitomee® Capsule A non-drug, clinically proven capsule that, by expanding in the stomach, helps users feel full, eat less, and stay on track FDA-cleared, CE and AMAR-approved, Rx medical device Drug-free, hormone-free, oral intake - no injection Integrates seamlessly into diet & exercise routines 1
Slide 12: Clinical Results for Weight Loss: 11.2% in 48 Weeks
Clinical Results for Weight Loss: 11.2% in 48 Weeks Sustainable Weight Loss Participants who completed 24 weeks of treatment with Epitomee® and lost at least 3%, joined the extension study for an additional 24 weeks and had lost 11.3% of baseline body weight after 24 weeks. With 24 additional weeks
Slide 13: Additional Epitomee Health Benefits in Peer-Reviewed Literature
Additional Epitomee ® Health Benefits in Peer-Reviewed Literature Early Waistline Weight Improved Improvement in Improvements in Safe & response3 reduction2,5 management 1-6 Quality of life4 Metabolic cardiometabolic drug-free1-6 syndrome 2 risk factors2 1. Ard JD, Ryan DH, O’Neil PM, et al. Efficac
Slide 14: Key Milestones Timeline
Key Milestones Timeline From FDA clearance, September 2024 to commercial rollout and a new growth strategy August 2026 US Online Pharmacy International Germany New Strategy Rafa Distribution Germany Orders FDA Clearance Revive agreement Shipments orders update Focus on aggressive Commercial agreemen
Slide 15: Commercial Rollout: OUS
Commercial Rollout: OUS Expansion Through Local Distributors 15
Slide 16: Israel: The Home-Base Market
Israel market Israel: The Home-Base Market The Opportunity: Almost 60% of Israelis are Overweight* 63% 57% 80% of Israeli men are overweight of Israeli women are overweight of diets for weight loss fail — weight regained within a year Go-to-Market: ISRAEL — The Home-Base Market Exclusive Distributor
Slide 17: Capturing Europe's Weight Management Opportunity
Capturing Europe’s Weight Management Opportunity $8B+ $22B 12% CAGR European GLP-1 market revenue (2025) Projected GLP-1 market size by 2033 Rapid growth through 2033 Our Go-to-Market Strategy Market Approach Distribution Partners Operations Localized strategies tailored to Partnering with early-ado
Slide 18: US Market Entry Strategy: DTC Telehealth & Distribution Partnerships
US Market Entry Strategy: DTC Telehealth & Distribution Partnerships Model 18
Slide 19: Four High-Intent Personas Already Spending
TARGET CUSTOMERS Four High-Intent Personas Already Spending We will not outspend pharma on broad reach; we win by tailoring messages to segments already paying for sub-optimal alternatives. GLP-1 Intolerants PRIMARY TARGET BMI 25–30 “Orphans” STRUCTURAL OPENING Severe GI effects, muscle loss, reboun
Slide 20: US TeleHealth Go-to-Market Strategy
US TeleHealth Go-to-Market Strategy A streamlined operation driven by targeted digital marketing and telehealth platform 1 2 3 4 Discover Asynchronous prescribing Fulfillment Deliver Targeted DTC ads via Meta, and Turn-key provider Physician approves prescription; Epitomee Capsule shipped directly G
Slide 21: A new approach to weight management
Anew approach to weight management. INGESTING epitemee epitemee e v 2-3in. Reduced in waistline in the first 24 weeks” epitemee ‘weight management capsule
Slide 22: A breakthrough in healthy, non-drug weight management
A breakthrough in healthy, non-drug weight management. The Epitomee* Capsule With two 8-ounce (250 ml) Balanced Nutrition glasses of water Regular healthy 30 minutes eating habits with before lunch a focus on and dinner. balance. oa ° Safe. Simple. Clinically-proven. Clinically-Proven Results No sti
Slide 23: US 1st Partnership: Revive Health
US 1st Partnership: Revive Health What is Revive? An integrated healthcare platform, providing health services for employers. serving 1,600+ Employers (US companies) and 4M members – (employees). Via virtual care designed for self-insured employers Revive partnership Launch Q3-Q4 2026* Integrating t
Slide 24: Manufacturing Scale-Up: State-of-the-Art Production Process
Manufacturing Scale-Up: State-of-the-Art Production Process Raw material Thin film coating Robotic assembly
Slide 25: Estimated Manufacturing Capacity: Scale-Up Plan
Estimated Manufacturing Capacity: Scale-Up Plan Estimated Manufacturing capacity (in thousands boxes) 1000 ~48M Capsules 900 800 Thousands boxes 700 600 50k Boxes ~2.7M ~24M Capsules ~24M Capsules Capsules. 500 At the end of 2026, we 400 estimate a yearly ~15M Capsules 864 Manufacturing 300 capacity
Slide 26: Slide 26
Slide 27: Understanding Scale
Understanding Scale epitemee
Slide 28: Business Case: Unit Economics to Scale
Business Case: Unit Economics to Scale The indicated revenue in this illustration assumes direct online sales at $100-$300 per 4-week cycle Per Patient Revenue At Scale Revenue ($100-$300) per 4-week cycle 10K Patients (12-month), 6.7M Caps/Year 6-Month User ~10K Patients ~$12M - ~$36M /year $600 -
Slide 29: US Market Penetration Potential
US Market Penetration Potential The indicated revenue in this illustration assumes direct online sales at $100-$300 per 4-week cycle # of 12-month patients served US Market penetration* Annual revenue ~35k pts, ~24M ~0.02%* ~$43M - ~$128M This is WITHIN short-to-mid-term caps standalone capacity Thi
Slide 30: Next Steps: Accelerating Growth
Next Steps: Accelerating Growth 30
Slide 31: 2026 Milestones & Timeline
2026 Milestones & Timeline Home Market Global Expansion: US Market Launch ROW & EU Penetration Strategic collaboration with Secure new partnerships and expand Launch Revive online pharmacies Rafa into untapped international territories and employer healthcare* 1 2 3 4 5 Scale Telehealth USA Manufact
Slide 32: Oral Delivery of Biologics: Solution
Oral Delivery of Biologics: Solution 32
Slide 33: A Platform Technology with Various Applications
A Platform Technology with Various Applications Oral Biologics Drug carrier for delivery in the small intestine ORAL ADMINISTRATION TARGETED DEPLOYMENT Easy ingestion with no clinical procedures Precise delivery to specific therapeutic location Phase-1 Strategic Moves Preparations for Research colla
Slide 34: Why Epitomee is Primed for Success
Why Epitomee is Primed for Success • Substantial growth potential in a vast and expanding market • Highly scalable operational growth model • Defined roadmap toward profitability • Comprehensive strategy for market expansion The highlights presented on this slide, including but not limited to projec
Slide 35: Thank you
Thank you Corporate Deck, January 2026 35
Epitomee Medical — Investor Presentation (September 2026) on 6ix